Akari Therapeutics Statistics
Share Statistics
Akari Therapeutics has 14.44K
shares outstanding. The number of shares has increased by 306427.39%
in one year.
| Shares Outstanding | 14.44K |
| Shares Change (YoY) | 306427.39% |
| Shares Change (QoQ) | 225888.37% |
| Owned by Institutions (%) | 0.26% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,184 |
| FTD / Avg. Volume | 3.85% |
Short Selling Information
The latest short interest is 76.99K, so 0.27% of the outstanding
shares have been sold short.
| Short Interest | 76.99K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.44% |
| Short Ratio (days to cover) | 5.25 |
Valuation Ratios
The PE ratio is -0.74 and the forward
PE ratio is null.
Akari Therapeutics's PEG ratio is
0.04.
| PE Ratio | -0.74 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0.66 |
| P/FCF Ratio | -1.16 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Akari Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15,
with a Debt / Equity ratio of 0.15.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.26 |
| Interest Coverage | 88.7 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,473,875 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -5.44% in the
last 52 weeks. The beta is 0.58, so Akari Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | -5.44% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 2.04 |
| Relative Strength Index (RSI) | 58.22 |
| Average Volume (20 Days) | 30,732 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.64M |
| Net Income | -19.79M |
| EBITDA | -21.64M |
| EBIT | -20.04M |
| Earnings Per Share (EPS) | -1.6 |
Full Income StatementBalance Sheet
The company has 2.6M in cash and 3.26M in
debt, giving a net cash position of -661K.
| Cash & Cash Equivalents | 2.6M |
| Total Debt | 3.26M |
| Net Cash | -661K |
| Retained Earnings | -247.25M |
| Total Assets | 50.56M |
| Working Capital | -16.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.55M
and capital expenditures 0, giving a free cash flow of -12.55M.
| Operating Cash Flow | -12.55M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.55M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
